MaaT Pharma, a clinical-stage biotech company focused on the development of Microbiome Ecosystem Therapies (MET) dedicated to improving survival outcomes for patients with cancer, is now a member of Microbiome Therapeutics Innovation Group (MTIG).
London-based precision medicine software provider Lifebit has partnered with two population genomic initiatives in Mexico and Brazil to help diversify genomic research and reduce health inequality in Latin America.
Twist Bioscience, a biotech company manufacturing synthetic DNA, and Cancer Research Horizons, the innovation engine at the core of Cancer Research UK, have announced an agreement under which Cancer Research Horizons will license the entire Twist Biopharma...
Johnson and Johnson (J&J) recently granted permission to Stop TB Partnership to distribute its generic TB drug bedaquiline (SIRTURO) to the majority of low- and middle-income countries.
UK contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions, has completed the build of its new development and GMP manufacturing headquarters in Nottingham, UK.
Crossbow Therapeutics, a biotech company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, has announced a $80 million Series A funding round.
Japan’s Ministry of Health, Labour, and Welfare approved FluMist Quadrivalent in March 2023, marking the first approval of an intranasal vaccine in the country’s history.
BioCardia has recently completed the submission of CardiAMP Cell Therapy System to Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards approval for the indication of ischemic heart failure (HF) with reduced ejection fraction.
Contract development manufacturer of nanomedicines, Ardena, has joined forces with mRNA and LNP technology specialists RiboPro, to form a new strategic commercial alliance.
Inspired Thinking Group (ITG) the technology-led multichannel marketing activation business, has launched ITG Health to deliver an ‘automation-first approach’ to the life sciences industry.
Biotechs located in the US received 19% or $7.6 billion more venture financing from 2018-2023 (YTD) for biologic innovator drugs compared to small molecule counterparts, driven by inflation law to drive down prescription drug prices, reveals GlobalData....
Last month, CDMO giant Samsung Biologics revealed it was planning to have its fifth plant operational by April 2025, five months earlier than previously anticipated.
Lucy Jung is the CEO and founder at Charco Neurotech, a medtech start-up which has developed the CEU1, a wearable device for Parkinson's, that uses vibrotactile stimulation to reduce symptoms of slowness and stiffness - resulting in improved movement....
Donaldson, a provider of filtration products and solutions, has acquired Univercells Technologies, a producer of biomanufacturing solutions for cell and gene therapy research, development, and commercial manufacturing, to broaden its life sciences reach....
Astraveus, the creator of modular, microfluidic cell foundries for cell and gene therapy (CGT) manufacturing, has raised €16.5 million in series seed financing.
Oliva Therapeutics, a healthcare company focused on product commercialization, sales, marketing, distribution, and promotion, has announced its new long-term partnership with Rio Biopharmaceuticals, for the exclusive North American supply and distribution...
CStone Pharmaceuticals' shares have risen after academic journal Nature Cancer published the clinical study results of its lung-cancer treatment sugemalimab.
With both GSK and Pfizer recently gaining FDA approval for their respective respiratory syncytial virus (RSV) vaccines, the stakes are high for competition in the sector.
Adede is a seasoned computer scientist and data professional known for providing high quality service whilst employing her multi talents which include efficiency, analytical thinking, and fast learning.
Adede is a seasoned computer scientist and data professional known for providing high quality service whilst employing her multi talents which include efficiency, analytical thinking, and fast learning.
Samsung Biologics’ upcoming fifth plant will be operational by April 2025, five months earlier than previously expected, the biotech company revealed at BIO International Convention on Monday 5.
Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs).
Sales of branded anti-obesity drugs (AOB) could hit $44 billion in 2030 vs. $2.5 billion in 2022, with just under 70% stemming from the US, according to a report from Bloomberg Intelligence.
Scarlet Therapeutics, a leader in red blood cell-based therapeutics, has raised seed funding from Science Creates Ventures and Meltwind to develop its platform and build a pipeline of novel therapies.
HexisLab, a UK biotech company, has secured a £490,000 funding grant from Innovate UK to develop a scale-up manufacturing process for its novel sustainable and green ingredients.
Waters Corporation has officially completed its acquisition of Wyatt Technology, a leading provider of light scattering and field-flow fractionation instruments, software, accessories, and services.
In first quarter 2023 financials, the company reported a drop in net revenue of close 10%, as the impact of Humira biosimilar entry onto the market begins to bite.
After decades of respiratory syncytial virus (RSV) vaccine research, a vaccine candidate for RSV developed by GSK, Arexvy, has become the first of its kind to be approved globally.
The Japanese pharmaceutical giant Astellas Pharma has taken over the U.S. company Iveric Bio in a $5.9 billion deal to get hold of its ophthalmology-focused pipeline.
bluebird bio has announced the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for lovotibeglogene autotemcel (lovo-cel) gene therapy in patients with sickle cell disease (SCD).
The South Korean company is set to create a new facility in West Virginia to house insulin manufacturing and to deliver its insulin products in the country.
The modification of an existing collaboration agreement with AstraZeneca gives Sanofi full commercial control of RSV antibody Beyfortus (nirsevimab) and 'enhanced agility' in the US market.
Ginkgo acquires StrideBio's adeno-associated virus (AAV) capsid discovery and engineering platform assets and as well as gaining ownership of a preclinical asset.
